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When we talk about drug addiction, we are really dealing with an extremely complex sys-
tem in which there still remain many unknowns and where many empty spaces or missing
links are still present. Recent studies have identified changes in the expression profiles of
several specific miRNAs which affect the interactions between these molecules and their
targets in various illnesses, including addiction, and which may serve as valuable targets for
more efficient therapies. In this review, we summarize results which clearly demonstrate
that several morphine-related miRNAs have roles in the mechanisms that define addiction.
In this regard, morphine has been shown to have an important role in the regulation of dif-
ferent miRNAs, such as miR-let-7 [which works as a mediator of the movement of the mu
opioid receptor (MOR) mRNA into P-bodies, leading to translational repression], miR-23b
(involved in linking MOR expression and morphine treatment at the post-transcriptional
level), and miR-190 (a key post-transcriptional repressor of neurogenic differentiation, Neu-
roD). Fentanyl increases NeuroD levels by reducing the amount of miR-190, but morphine
does not affect the levels of NeuroD. We also discuss the relationship between morphine,
miRNAs, and the immune system, based on the discovery that morphine treatment of
monocytes led to a decrease in several anti-HIV miRNAs (mir-28, 125b, 150, and 382).
This review is centered on miR-133b and its possible involvement in addiction through the
effects of morphine. We establish the importance of miR-133b as a regulatory factor by
summarizing its activity in different pathological processes, especially cancer. Using the
zebrafish as a research model, we discuss the relationship between mir-133b, the dopamin-
ergic system, and morphine, considering: (1) that morphine modulates the expression of
miR-133b and of its target transcript Pitx3, (2) the role of the zebrafish mu opioid recep-
tor (zfMOR) in morphine-induced regulation of miR-133b, which depends on ERK1/2, (3)
that morphine regulates miR-133b in hippocampal neurons, and (4) the role of delta opioid
receptors in morphine-induced regulation of miR-133b. We conclude that the control of
miR-133b levels may be a mechanism for the development of addiction to morphine, or
other drugs of abuse that increase dopaminergic levels in the extracellular space. These
results show that miR-133b is a possible new target for the design of new treatments
against addictive disorders.
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INTRODUCTION
OPIOIDS
Opioids are the most potent compounds known today to control
pain, and are also amongst the most used drugs of abuse (Corbett
et al., 2006). They bind to the three classical opioid receptors, mu
(MOR), delta (DOR), and kappa (KOR).
It has been established that the MOR displays higher affinity
toward morphine than the other classical opioid receptors, delta,
and kappa. Also, an interaction between the mu and the DOR
has been described in vitro, which is thought to be responsible for
faster development of morphine tolerance through the mu opi-
oid receptor (Waldhoer et al., 2004). Moreover, when DOP are
knocked out, mice do not develop tolerance to morphine and do
not suffer the withdrawal effect once long-term treatment with
morphine is over (Fundytus et al., 1995).
After establishing the pharmacological profiles of these clas-
sical opioid receptors, investigators studied post-transductional
mechanisms, such as receptor internalization and desensitization.
Later, interest focused on the intracellular effectors that mediate
the activation of signaling cascades. It has been suggested that these
post-transductional mechanisms are closely linked to the develop-
ment of opiate tolerance and dependence on opiate drugs, mainly
through the same plasticity mechanisms that produce adaptive
changes in neural circuitries, for example, in memory and learning
(Evans, 2004).
After more than 40 years of intense research on opiates, sci-
entists now partly understand their mechanism of action on
receptors.
Many issues concerning the mechanisms of addiction still
remain to be established. This can be achieved by analyzing the
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different roles of the opioid receptors apart from their involvement
in analgesic properties, such as their functions in developmental
processes. For instance, the MOR and KOR increase neurogenesis
(Kim et al., 2006), and the DOR acts as a neuroprotector (Narita
et al., 2006). Also, other drugs of abuse, such as amphetamines,
cocaine, or heroin, produce neuroadaptive changes in the brain
that could be explained by shared gene regulatory mechanisms
that lead to addiction. In this sense, opioid receptor gene regula-
tion has been reported to be concurrently related to miRNAs and
to the addiction process (Zheng et al., 2010b; Sanchez-Simon et al.,
2010).
MORPHINE
There are a wide variety of opiates, classified according to their
origin and/or structure. The main natural opiates are morphine,
phenanthrenic alkaloids similar to morphine (codeine and the-
baine), and benzylisoquinolinic alkaloids (noscapine and papaver-
ine). Semisynthetic opiates (heroin, hydrocodone, meperidine,
oxycodone, buprenorphine, and etorphine) have a morphine-like
structure, whereas fully synthetic opiates (methadone, fentanyl,
tramadol, metazocine, and pentazocine) display a wide range of
unrelated structures that show similar pharmacological proper-
ties. Unfortunately, opiates present some undesirable side effects,
such as tolerance, dependence, and addiction (Nestler et al., 1993).
Thus, there is a need for novel analgesic drugs that do not have
these adverse side effects, especially in light of the widespread abuse
of opiates.
The opioid alkaloide Morphine is the main active compound
in opium, the juice obtained from the seed of the poppy plant
Papaver Somniferum, and has been used for centuries as a medical
and recreational agent. It is used both by medical patients suf-
fering acute or chronic pain, and by habitual daily abusers. Since
its isolation, morphine has been used largely for pain manage-
ment, although other, non-analgesic uses, including experimental
depression treatments and as a cure for opium addiction,have been
developed. Despite these common uses, morphine produces dis-
ruptive negative secondary effects including sleepiness or drowsi-
ness, blurred vision, constipation, and a decrease in blood pressure
and appetite. With continuous use, morphine produces physical
tolerance and addiction.
Accumulating evidence has demonstrated that, upon repeated
exposure to morphine, long-lasting neurochemical alterations
occur in discrete brain regions. Changes in gene expression are
likely to mediate these adaptations in brain neurochemistry,
thereby contributing to dependence and drug addiction (Nestler,
2004). However, the key intracellular signaling molecules that par-
ticipate in regulating the alterations in gene expression induced by
chronic opiate exposure remain unclear.
Recent studies (Dreyer, 2010; Hollander et al., 2010), mainly
based on cocaine activity, have reported a role for miRNAs in
drug addiction. This opens the door to possible miRNA-mediated
involvement of opioids – including morphine – in the addictive
process.
ADDICTION
Addiction to drugs is a major public health problem, and rep-
resents a complex disorder with multigenic causes. Even when
many humans are exposed to drugs of abuse, only some suffer
from loss of control over drug use and compulsion for drug seek-
ing and taking; factors that define the addictive situation. It is
known that addiction is influenced by both the genetic constitu-
tion and the social and psychological environment in which the
individual lives (Kendler et al., 2007). The pharmacological activa-
tion of brain rewards systems is largely responsible for producing
addiction after drug use. Personality, genetic, and social factors are
important, although drug effects in the CNS are thought to be the
fundamental determinants of addiction. The genetic contribution
to the risk for addiction is only close to 50% (Kendler et al., 2007),
but the specific genes that are involved in the addictive process are
almost completely unknown. Besides, the addictive phenotype can
persist even after long periods of abstinence, implying that drugs
induce long-lasting alterations in the brain that underlie addiction
behaviors (for reviews on this topic, see Dreyer, 2010; Robison and
Nestler, 2011).
miRNAs
MicroRNAs (miRNAs) are∼22 nucleotide (nt) non-coding RNAs
that participate in gene regulation. They bind to 3′ untranslated
regions (UTRs) of their mRNA targets, inhibiting the transcripts’
translation and/or destabilizing them (Valencia-Sanchez et al.,
2006). Numerous studies have shown that multiple binding sites
in the same 3′UTR confer much stronger regulation than sin-
gle binding sites (Fang and Rajewsky, 2011). However, reporter
assay experiments have suggested that miRNA targeting can also
occur in coding regions (Kloosterman et al., 2004; Easow et al.,
2007). Large-scale miRNA mis-expression studies also have sug-
gested that binding in coding regions can confer regulation but are
on average less effective than those in 3′UTRs (Baek et al., 2008;
Selbach et al., 2008). MiRNAs have been shown to regulate the
expression of many genes, including genes which function in the
CNS. For example, miR-134 regulates dendritic spine morphology
by controlling actin filament dynamics (Schratt et al., 2006), while
miR-190 regulates neurogenic differentiation (NeuroD), a tran-
scription factor that regulates the differentiation and maturation
of neurons (Zheng et al., 2010c).
Over 3000 mature miRNAs have been identified in species
ranging from plants to humans, suggesting that they have an
important role in gene regulation. At present, a better understand-
ing of miRNA biology, combined with the increasing availability
of diverse sequenced genomes, have revealed many of the molec-
ular mechanisms that underlie the evolution of miRNAs and their
targets (Berezikov, 2011) Although the molecular mechanisms of
miRNA activity are increasingly clear, the biological implications
of miRNAs activity are not yet fully defined; functions including
cell differentiation, proliferation, apoptosis, anti-viral defense, and
cancer have been proposed, and, to an extent, validated.
It has recently been shown that miRNAs are highly expressed
in the CNS, including the areas where opioid activity takes place:
the brain and spinal cord (Dave and Khalili, 2010; He et al., 2010;
Sanchez-Simon et al., 2010; Zheng et al., 2010b). Since the dis-
covery that miRNAs are important regulators of gene expression,
these molecules have been linked to biological processes such as
drug addiction (He et al., 2010; Zheng et al., 2010a), pain percep-
tion (Kusuda et al., 2011), neuron development (Gao, 2010), viral
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infection (Dave and Khalili, 2010; Wang et al., 2011), and opioid
receptor regulation (Wu et al., 2008; Sanchez-Simon et al., 2010).
Recent experimental work demonstrates that opioids modify
the expression profile of certain mRNAs in the CNS (Wu et al.,
2008; He et al., 2010; Sanchez-Simon et al., 2010). Also, recent
studies, including our own results, have implicated miRNAs in
addiction behaviors. Most importantly, miRNAs whose expression
is altered by opioids have been shown to regulate the expression of
many proteins involved in the addiction pathway (Li and van der
Vaart, 2011).
To understand the biological roles of miRNAs, it is essential
to identify their targets. Because only a few bases of complemen-
tarity are required between miRNAs and their target sequences,
mRNA targets can often be difficult to identify, computation-
ally or experimentally. The classical model for specific miRNA
target recognition by most algorithms mainly depends on (a)
the detection of seed matches and (b) the thermodynamic sta-
bility of miRNA: mRNA duplexes. Different algorithms usually
produce divergent results (Ambros, 2004; Bentwich, 2005; Rajew-
sky, 2006; Baek et al., 2008). As miRNA recognition elements are
typically found in the 3′ UTR of the target gene mRNA, bioin-
formatics alone can identify putative targets using resources such
as miRGen database. The number of putative targets for any one
miRNA has increased in recent years, making the interpretation of
miRNA activity more complex. A question to be asked at present
is, whether there is a relationship between the different targets
a miRNA binds to, and if so, what is the meaning of this situa-
tion. Further studies are need in this field in order to elucidate the
meaning of the fact that a certain miRNA has different, but perhaps
functionally related, target mRNAs. Improved software programs
are now able to predict the targets of miRNAs in a more efficient
manner, facilitating the elucidation of miRNA function. Bioin-
formatic predictions (Targetscan) suggest that miRNAs target at
least 60% of mammalian RNAs with conserved miRNA targets
(Friedman et al., 2009).
OPIOIDS AND miRNAs
miR-let-7
He et al. (2010) identified a let-7 binding site in the 3′-UTR of
the MOR mRNA and found that let-7 thereby represses MOR
expression. They also found that morphine significantly upreg-
ulates let-7 expression in SH-SY5Y cells and in a mouse model
of opioid tolerance. Inhibition of let-7 decreased brain let-7 lev-
els and partially attenuated opioid antinociceptive tolerance in
mice. Although chronic morphine treatment did not change over-
all MOR transcript levels, association of polysomes with MOR
mRNA declined in a let-7 -dependent manner. The miRNA let-7
works as a mediator moving MOR mRNA to P-bodies, leading
to translation repression. These results suggest that let-7 plays an
integral role in opioid tolerance.
miR-23b
The expression of MOR can be regulated at both the transcrip-
tional and post-transcriptional levels. Long-term morphine treat-
ment does not alter MOR mRNA levels (Brodsky et al., 1995),
suggesting that morphine itself has no important role in the tran-
scription of the MOR gene. Nevertheless, it has not yet been
elucidated whether morphine can regulate MOR mRNA at the
post-transcriptional level, by producing an interaction between
trans-acting factors and its 3′-UTR.
Wu et al., 2008, identified miR-23b as a trans-acting factor
that represses MOR translation efficiency through an interaction
with the K box motif in the 3′-UTR of MOR1. This interaction
suppresses receptor translation by inhibiting polysome-mRNA
association. Later, the same group demonstrated that long-term
morphine treatment increases miR-23b expression in a dose-
and time-dependent manner (Wu et al., 2009). Using a transla-
tional luciferase reporter assay, these authors observed morphine-
dependent suppression of reporter activity through the MOR1
3′-UTR. This finding suggests a link between MOR expression
and morphine treatment at the post-transcriptional level involving
miR-23b.
miR-190
Zheng et al. (2010b) have shown that fentanyl, but not morphine,
increases levels of one of the targets of miR-190, NeuroD. This
group also showed that by regulating NeuroD activity, mu opioid
receptor agonists modulate the stability of dendritic spines. This
work is discussed elsewhere in this chapter.
MORPHINE, miRNAs, AND THE IMMUNE SYSTEM
People addicted to opioids have a higher incidence of infectious
diseases, and opioids exert a profound influence in immunomod-
ulatory activity (Nair and Schwartz, 1997). In order to understand
the relationship between morphine, miRNAs, and the immune
system, the following features of morphine should be considered:
morphine inhibits specific immunocyte activities, such as mono-
cyte respiratory burst (Peterson et al., 1987), chemotaxis (Stefano
et al., 1996), and phagocytosis (Rojavin et al., 1993). In addition,
morphine induces apoptosis of macrophages and microglia (Hu
et al., 2001), decreases the levels of IFN-γ and interleukin-2 in
human T cells (Nyland et al., 2003), induces the expression of HIV
entry coreceptors in the immune cells, and facilitates HIV replica-
tion in vitro (Guo et al., 2002; Li et al., 2002; Persson et al., 2003;
Steele et al., 2003).
Wang et al. (2011), showed that morphine treatment in mono-
cytes leads to a decrease in several anti-HIV miRNAs (miR-28,
125b, 150, and 382). Interestingly, these same miRNAs were corre-
lated with the susceptibility of monocytes to HIV-1 infection. This
morphine-driven decrease in anti-HIV miRNAs disappears when
antagonists of the opioid receptors are used, indicating that mor-
phine functions through its own receptors. On the other hand, type
I interferon IFN-α/β, in monocytes could induce the expression of
these same anti-HIV miRNAs. Other studies have also shown that
type I IFNs modulate miRNA expression in several cell systems
(O’Connell et al., 2007; Pedersen et al., 2007; Ohno et al., 2009),
functioning as the potent inducer of miRNAs. However, morphine
co-treatment with IFN-α/β in monocytes inhibited the induction
of IFN-mediated anti-HIV miRNAs (Wang et al., 2011).
HIV-1 infected opiate abusers have potential to destabilize neu-
ronal functions, and often exhibit HIV-1 associated dementia (Bell
et al., 2006; Fitting et al., 2010).
Dave and Khalili, 2010 reported that in human monocyte-
derived macrophages treated with morphine, miR-15b expression
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levels were greatly increased. Fibroblast growth factor-2 (FGF-2),
identified as a miR-15b target gene, was decreased at the protein
expression levels in response to morphine. Another miRNA, miR-
181b, decreased its expression levels under the same conditions.
Later studies have shown that morphine induces inflammation
and oxidative stress in immune cells through regulating the miR-
15b and 181b, thereby contributing to expansion of the HIV-1
CNS reservoir and hence to AIDS progression.
miR-133b
miR-133 was first characterized in mice (Lagos-Quintana et al.,
2002), after which homologs were characterized in several other
species including invertebrates. Each species frequently encodes
multiple miRNAs with identical or similar mature sequences.
Three different miR-133 sequences are known: miR-133a-1,
miR-133b-2, and miR-133b.
A good example of the importance of miR-133b is represented
by the work of Yu et al. (2011b). They studied the function of
miR-133b during zebrafish spinal cord regeneration and showed
upregulation of miR-133b expression in regenerating neurons of
the brainstem after transection of the spinal cord. Inhibition of
miR-133b expression by antisense morpholino (MO) application
resulted in impaired locomotor recovery and reduced regeneration
of axons from neurons in the nucleus of the medial longitudinal
fascicle, superior reticular formation, and intermediate reticular
formation. They found that miR-133b targets the small GTPase
RhoA, which is an inhibitor of axonal growth, as well as other
neurite outgrowth-related molecules. These results indicate that
miR-133b is an important determinant in spinal cord regenera-
tion of adult zebrafish through a reduction in RhoA protein levels
by direct interaction with RhoA mRNA. These authors showed
that the ability of miR-133b to suppress molecules that inhibit
axon regrowth may underlie the capacity for adult zebrafish to
recover locomotor function after spinal cord injury (SCI).
MicroRNAs-133b plays an important role in several regulatory
processes. For example, in cardiomyocytes, miR-133b serves an
antiapoptotic role by inhibiting caspase-9 (Xu et al., 2007). Among
its multiple targets, miR-133b down-regulates RhoA protein
expression (Care et al., 2007; Chiba et al., 2009). RhoA is strongly
upregulated following SCI (Conrad et al., 2005; Erschbamer et al.,
2005), and inhibition of RhoA enhances regrowth of the corti-
cospinal tract and promotes neuroprotection by decreasing the tis-
sue damage and cavity formation that develop after SCI (Dergham
et al., 2002; Fournier et al., 2003; Tanaka et al., 2004; Hoffmann
et al., 2008; Holtje et al., 2009). Considering that multiple cellu-
lar and molecular pathways are regulated by miRNAs, and that
the targets of miR-133b are conserved throughout development
in different species from zebrafish to mammals, it could be con-
sidered that these results (such as Yu et al., 2011b) may guide the
development of novel strategies for improving functional recovery
after SCI in humans. The extent to which miR-133b is involved
in multiple pathological phenotypes is outstanding and highly
noteworthy. Table 1 represents a summary of the involvement of
miR-133b in relation to different pathological situations. Recent
reports show that some miRNAs control major cancer-related sig-
naling molecules, such as epidermal growth factor (Erkan et al.,
2011),members of the p53 family (Inui et al., 2010; Ory and Ellisen,
2011), and the retinoblastoma protein (Noonan et al., 2010). In
cancer, miRNAs can be divided in two separate classes: those that
are tumor suppressive and those that are oncogenic. MiR-133b can
participate in both systems, depending whether it is overexpressed
(act as oncogenes, repressing tumor suppressor genes),or underex-
pressed (functioning as a tumor suppressor, negatively regulating
oncogenes). Table 1 summarizes recent research regarding the role
of miR-133b in multiple pathologies, including cancers. Table 2
lists cancers in which miR-133b exerts direct regulation.
The relationship of miR-133b with cancer is important to the
topic of this chapter, since morphine and the synthetic compound
Table 1 | Involvement of miR-133b in different physiological situations.
Situation Reference
Translational regulation of utrophin: miR-133b, related
to Duchenne muscular dystrophy, mediates the
repression, and confirms repression of miR-206
Basu et al.
(2011)
Formation of homologue clusters with miR-206:
dysregulation role
Nohata et al.
(2012)
Upregulation during late stages of human, fetal
muscle development
Koutsoulidou
et al. (2011)
When downregulated, miR-133b may have important
implications in pathogenesis of essential hypertension
Yu et al. (2011a)
Co-regulation of miR-133b with miR-206, novel
biomarkers of Th 17-type immune reactions
Haas et al.
(2011)
Desregulation of miR-133b is associated with overall
survival and metastasis in colorectal cancer
Akcakaya et al.
(2011)
Increase of miR-133b in mouse pectoralis muscle:
regulation by myostatin
Rachagani et al.
(2010)
Upregulated miR-133b in mouse liver by tyrosine
hormone
Dong et al.
(2010)
MiR-133b is upregulated on head and neck cancer Liu et al. (2009)
Mir-133b is regulated by endurance exercise in human
skeletal muscle
Nielsen et al.
(2010)
Mir-133b is a biomarker of myocardial infection D’Alessandra
et al. (2010)
MiR-133b targets prosurvival molecules MCL-1 and
BCL262 in lung cancer
Crawford et al.
(2009)
Table 2 | Downregulation of miR-133b in different cancers.
Type of cancer Reference
Colorectal cancer Suzuki et al. (2011); Hu et al. (2010);
Bandres et al. (2006); Sarver et al. (2009)
Bladder cancer Song et al. (2010)
Gastric cancer Wu et al. (2011a)
Lung cancer Nasser et al. (2008); Crawford et al.
(2009); Wu et al. (2011b)
Esophageal squamous cell
carcinoma
Kano et al. (2010)
Tongue squamous cell
carcinoma
Wong et al. (2008)
Head and neck squamous cell
carcinoma
Nohata et al. (2011)
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fentanyl are widely used as the analgesic solution for long-term
pain suffering in cancer patients, and it is well known that these
drugs produce addiction after long-term use. MiR-133b can act
as an oncogene or as a tumor suppressor, making the interaction
between this miRNA and morphine crucial in the control of a
defined cancer pathology. Morphine, not only because it produces
addiction, but also because of its own oncogenic effect, can be con-
sidered a negative analgesic tool in some cancer patients. Future
research is needed to elucidate how to overcome this possibility.
ZEBRAFISH AS A MODEL TO STUDY THE RELATIONSHIP
BETWEEN miR-133b AND MORPHINE
Although great efforts have been made on the study of the different
mechanisms that are activated by the opioid system in mam-
malian models, many issues regarding opioid regulation remain
unknown. The zebrafish (Danio rerio) has been used as an exper-
imental model, not only to study genetics and development, but
also to study disease-related pathways, given its easy in vivo manip-
ulation. In this sense, the zebrafish can be an important tool to
analyze in vivo the molecular mechanisms related to the activity
and function of the opioid system that cannot be fully established
in other models. For instance, in contrast to mammalian embryos,
which develop in the uterus and are influenced by the mater-
nal biochemical processes, zebrafish embryos develop externally,
avoiding the maternal effect on these embryos. This is essential
when dealing with drug exposure, as the effects observed in mam-
malian embryos might be due to the susceptibility of the mother
and not the embryo per se. The study of the morphine direct effects
in the embryos will provide a better understanding on the mole-
cular mechanisms that underlie the physical and neurobehavioral
defects shown in fetuses and offspring after maternal morphine
consumption (Nasiraei-Moghadam et al., 2010). Also, the endoge-
nous opioid system has been characterized in the zebrafish, and
contains a mu opioid receptor (zfMOR), two DOR duplicates
(zfDOR1 and zfDOR2), a kappa opioid receptor (zfKOR) and an
opioid receptor like (zfORL) gene (Barrallo et al., 2000; Rodriguez
et al., 2000; Alvarez et al., 2006; Pinal-Seoane et al., 2006). Hence,
the presence and the existing extensive characterization of opioid
receptors in zebrafish allow us to extrapolate key components of
the opioid system to other biological models.
OPIOIDS AND THE DOPAMINERGIC SYSTEM
The opioid-addiction pathway has been suggested to involve the
midbrain dopaminergic neurons located within ventral tegmen-
tal areas and the nucleus accumbens (NAc). The alteration of
dopamine levels in this region can produce neuronal sensitiza-
tion or desensitization, depending on the drug used. It has also
been established that morphine increases dopamine level through
the mu opioid receptor in the NAc, which may mediate reinforc-
ing effects of morphine (Gianoulakis, 2009). Relevant to these
observations, endogenous opioid peptides, such as enkephalins or
dynorphins, are upregulated in the NAc after exposure to mor-
phine, and modulate dopamine release in the midbrain (Gieryk
et al., 2010).
Hence, studies on the probable opioid regulation of dopamin-
ergic activities in zebrafish could provide insights on mammalian
embryonic development during chronic exposure to drugs.
miR-133b AND THE DOPAMINERGIC SYSTEM
miR-133b, regulates the differentiation, maturation, and function
of dopaminergic neurons by downregulating the transcription of
its target in the dopaminergic system, the homeobox gene pitx3
(Hebert and De Strooper, 2009). Pitx3 activates the transcription
of genes directly involved in the differentiation of dopaminergic
neurons (Figure 1), such as the tyrosine hydroxylase (th) and the
dopamine transporter (dat ; Kim et al., 2007).
Taking the above into consideration, we analyzed the effect of
morphine on the miR-133b regulatory pathway using zebrafish
embryos as a model building on well-established precedents for
using zebrafish to study the role of miRs in development (Schier
and Giraldez, 2006). At 24 h post fertilization (hpf), the dopamin-
ergic system begins its differentiation and the first TH- positive
neurons begin to be detected at this particular developmental
stage (Filippi et al., 2007). Our previous studies also indicated
that at 24 hfp, the expression of zfMOR, the putative target of
morphine (de Velasco et al., 2009) is increased. Therefore, the use
of 24 hpf zebrafish embryos provided information on the impli-
cation of the opioid system in the maturation and differentiation
of dopaminergic neurons compared to any other stages of devel-
opment, and also, demonstrated that the mu opioid receptor is
functional in zebrafish and has a specific role in the develop-
ment of the CNS and represents a possible pathway that leads
to addiction.
MORPHINE MODULATES THE EXPRESSION OF miR-133b
By means of a miRNA array, we observed a decrease in the expres-
sion of several miRNAs after embryonic exposure to morphine at
three developmental stages: 16, 24, and 48 hpf. Considering the
pathways in which each miRNA could be involved, we focused
on miR-133b due to its reported effect on dopaminergic neurons,
an essential component in drug addiction processes. Our studies
were carried out in the 24 hpf embryos, when differentiation of
the zebrafish CNS begins.
After validation by qPCR of our microarray results, we observed
that miR-133b level was decreased in 24 hpf embryos exposed to
morphine, at two different morphine concentrations; 10 and 1 nM.
The antagonist naloxone did not significantly change the expres-
sion of this miR, but it could block the morphine effect. Although
more selective agonists such as DAMGO or antagonists such as
CTOP were not used to define the receptor involved due to the
lack of affinity of such ligands for zfMOR (de Velasco et al., 2009),
the effect of morphine on miR-133b level was probably mediated
by the activation of zfMOR.
MORPHINE MODULATES THE EXPRESSION OF miR-133b
TARGET PITX3
The transcription factor Pitx3 is a known miR-133b target. Pitx3
has been regulates the transcription of th and dat. Since miRNAs
normally regulate the stability or the translation of the transcripts,
by reducing miR-133b morphine should either increase the lev-
els or the activities of these transcripts. Treatment of zebrafish
embryos with 1 and 10 nM morphine increases the mRNA levels of
pitx3 and dat while morphine treatment decreases miR-133b level.
Addition of naloxone effectively abolished the morphine-induced
changes in the expression levels of miRNA-133b, pitx3, th, and dat,
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FIGURE 1 | (A) Duplex sequence of miR-133b, formed by 84
ribonucleotides. Mature miRNA is shown in red. (B) miR-133b inhibits
the expression of transcription factor Pitx3, whose function is to
activate the expression of tyrosine hydroxylase (TH), the dopamine
transporter (DAT), the dopaminergic receptor (DRD2), the monoamine
vesicular transporter type 2 (VMAT2), and the aldehyde
deshydrogenase 2 (ADH2). These genes determine the neuronal
differentiation to the dopaminergic phenotype, so that when miR-133b
is expressed, the expression of the other genes is inhibited and hence,
dopaminergic differentiation is blocked.
suggesting that morphine regulates the level of the dopaminergic
genes via the control of miR-133b by activating zfMOR.
Although treatment of embryos with morphine clearly
decreases the miR-133b level and increases Pitx3 and its targets
TH and DAT levels, whether miR-133b indeed interacts with Pitx3
thereby destabilizing the transcript has not been demonstrated in
zebrafish.
THE ROLE OF zFMOR IN MORPHINE-INDUCED REGULATION
OF miR-133b PATHWAY
The effects of morphine on embryos are probably mediated by
zfMOR, the opioid receptor that exhibits highest affinity toward
morphine (de Velasco et al., 2009). In order to establish the
role of zfMOR in regulating miR-133b without the availability
of a zfMOR selective antagonist, we silenced (knocked down)
zfMOR by morpholino oligonucleotide injection. The efficiency
of the morpholino oligonucleotide to decrease the zfMOR level
was determined with qRT-PCR. Injection of 0.2µM of the mor-
pholino oligonucleotide per embryo reduced the zfMOR tran-
scription level by 95% (the injection of ZfMOR decreased the
expression of both ZfDOR1 and ZfDOR2 by ∼2.5%, which is
not statistically significant, showing the specificity of the zfMOR
morpholino).
The amount of miR-133b increases within embryos when
zfMOR is absent. Such an increase was not observed after the injec-
tion of a control morpholino. Furthermore, 1 or 10 nM morphine
exposure did not alter the miR-133b level in embryos injected with
zfMOR morpholino, while the same concentrations of morphine
treatment resulted in a decrease of miR-133b levels in embryos
injected with control morpholino. The increased expression in
miR-133b detected in the zfMOR knock down embryos also led to
a decrease of the subsequent miR-133b targets, i.e., Pitx3, TH, and
DAT. Clearly, the morpholino and the opioid antagonist naloxone
studies indicate zfMOR is the mediator for the morphine-induced
regulation of miR-133b and its targets.
MORPHINE-INDUCED REGULATION OF THE miR-133b
PATHWAY DEPENDS ON ERK1/2 ACTIVITY
Morphine, regulates multiple signaling pathways via the mam-
malian receptor MOR. In the rat hippocampus,morphine activates
ERK1/2 and decreases the expression level of miR-190 (Zheng
et al., 2010b). Whether similar signaling mechanisms are involved
in morphine-induced regulation of the miR-133b pathway in
zebrafish is unknown. In order to address this possibility, we used
several MAPK inhibitors, such as JNK inhibitor II, SB203580 for
p38 and PD98059 and U0126 for ERK1/2, to identify the sig-
nals involved in morphine-induced miR-133a regulation. The
inhibition of JNK and p38 produced a significant decrease in
the miR-133b level, and hence, an increase in the level of Pitx3,
TH, and DAT. In contrast, the inhibition of MEK1/2 by either
U0126 or PD98059 enhanced miR-133b expression, and as a con-
sequence, it decreased the level of Pitx3, TH, and DAT transcripts
(Figure 2).
Parallel treatment of embryos with morphine in the presence
of either JNK or p38 inhibitor did not eliminate the morphine-
induced decrease in the miR-133b level. Probably, by activat-
ing zfMOR, morphine, via the ERK1/2 pathway, regulates the
miR-133b level in the zebrafish embryos.
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FIGURE 2 | Schematic representation of the mechanism by which
morphine regulates the differentiation of dopaminergic neurons
through the control of the miR-133b expression and the transcription
of the genes regulated by this miRNA (Pitx3,TH, and DAT). (A)
Activation of ERK1/2 signaling by MOR reduces the expression of
miR-133b, and hence increases the transcription level of its target, Pitx3.
This transcription factor enhances the expression of TH and DAT. (B)
Silencing MOR by specific morpholinos produces an increase in the
expression of miRNA-133b, and reduces the transcription level of Pitx3,
TH, and DAT. (C) Inhibition of ERK1/2, even when the MOR receptor is
activated by morphine, produces the same effect as knockdown of the
receptor, i.e., the expression of miR-133b increases, and hence, the
expression of Pitx3, TH, and DAT decreases, which reduces the level of
dopaminergic neuron differentiation.
MORPHINE REGULATES miR-133b EXPRESSION IN HIPPOCAMPAL
NEURONS
When using zebrafish as a research model, there is always the
question of whether a mammalian counterpart for the observed
results exists. In order to determine whether the observed regu-
lation of miR-133b by zfMOR in the zebrafish embryos has any
mammalian counterparts, hippocampal neurons obtained from
P1 rats were treated with 100 nM morphine. Similar to previously
reported studies using mature hippocampal neuron cultures from
mice chronically treated with morphine, in which miRNA array
and qRT-PCR studies did not reveal any effect on the miR-133b
level (Persson et al., 2003), our current studies with mature, dif-
ferentiated neurons (3-week culture) revealed no effect on the
expression of miR-133b when treated with morphine. However,
he level of miR-133b was decreased in 1-week-old neurons treated
with morphine. Thus, similar to what we have observed in the
zebrafish embryos, only the miR-133b level within the immature
neurons was affected by morphine treatment.
miR-133b AND THE DELTA OPIOID RECEPTOR
Although the mu opioid receptor displays higher affinity toward
morphine than the other classical opioid receptors, delta, and
kappa, an interaction between the mu and the DORs has been
described in vitro. This interaction is thought to be responsible
for faster development of morphine tolerance via the mu opioid
receptor (Waldhoer et al., 2004). Moreover, knock-out mice for the
DOR do not develop tolerance to morphine and do not suffer the
withdrawal effect once the long-term treatment with morphine is
over (Fundytus et al., 1995). Despite knowledge acquired in the
past decade on the mechanisms that define opioid activity, many
issues concerning the mechanisms of addiction need to be estab-
lished. These goals may be achieved by analyzing the different roles
of the opioid receptors apart from their analgesic functions, such
as their involvement in developmental processes. For instance, the
MOR and KOR increase neurogenesis (Kim et al., 2006), and the
DOR acts as a neuroprotector (Narita et al., 2006). We have found
that morphine protects dopaminergic neurons against glutamate-
induced neurotoxicity, and this effect is mediated by the DORs
(unpublished). As the mu opioid receptor regulates dopaminergic
differentiation and the DORs protect these neurons, we searched
for an explanation of how the DORs relate to the adverse effects
of morphine.
ROLE OF THE DORS IN MORPHINE-INDUCED REGULATION OF miR-133b
PATHWAY
We have studied the role of the DORs from zebrafish in the expres-
sion of miR-133b and the genes downstream in its regulatory
pathway, in order to determine the specific influence of each delta
receptor duplicate as a regulator of this pathway. By knocking
down each DOR duplicate, both separately and simultaneously, we
demonstrated that they activate the differentiation of dopaminer-
gic neurons. Their complete absence increases miR-133b levels
and therefore, decreases the mRNA levels of the genes involved in
such differentiation (pitx3, th, and dat ). However, when only one
DOR is knocked down, morphine slightly decreases the expres-
sion of miR-133b, as detected in the control embryos and embryos
injected with the control morpholino. These results suggest that
when one DOR is not present, the other one functionally comple-
ments its role. Partial functional complementation may explain
why, although some changes are observed regarding the expression
of miR-133b and its related genes, these changes are not constant
in untreated and morphine-treated embryos. In contrast, when
both DORs are silenced, the effect produced is similar to that
observed when the mu opioid receptor is knocked down, suggest-
ing that both types of receptors, mu and delta, are involved in the
differentiation of dopaminergic neurons.
CONCLUSION
At present, evidence for the involvement of miRNAs in drug addic-
tion is markedly increasing (Schaefer et al., 2007; Dreyer, 2010;
Hollander et al., 2010), although these reports are mainly associ-
ated with cocaine. Aside from what we discussed in this review,
there has been no direct report concerning opioid addiction.
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Within the context of the dopaminergic system’s role in addic-
tive disorders, including addiction to morphine (Flores et al.,
2004; Leggio et al., 2009), we have established a pathway that may
account for the observed morphine-induced increase in dopamine
production (Gianoulakis, 2009). By modulating miR-133b regu-
latory pathways, and hence, dopaminergic differentiation, zfMOR
has a specific role in the CNS and is capable of regulating
transcription through miRNAs.
Our results lead us to conclude that the consequences of mater-
nal morphine intake on the fetus could take place through the
intracellular pathways of miR-133b and Pitx3. As our results sug-
gest, neonate abstinence syndrome might be caused by the alter-
ation in dopaminergic differentiation, induced by morphine. In
addition, inhibition of ERK1/2 shows that, the closer the treatment
to the timing of early CNS differentiation, the greater is the effect
of this inhibition on the expression levels of the genes involved in
the maturation and differentiation of dopaminergic neurons.
These data point out the importance of the developmental stage
at which embryos are exposed to drugs, as exposure at different
stages varies the impact of such drugs on the embryo’s devel-
opment. Thus the control of miR-133b level could be a possible
mechanism responsible for the development of addiction to mor-
phine or to other drugs of abuse that increase dopamine levels in
the extracellular space. These results show for the first time that the
miR-133b is a possible new target for the design of new treatments
against addictive disorders.
The differences in the effect of morphine on miR-133b expres-
sion of in 1-week and 3-week rat neurons demonstrate that mor-
phine induces differentiation by decreasing the expression of this
particular miRNA only in the immature neurons. Therefore, the
effects of morphine consumption during pregnancy may impact
neuronal differentiation, through inducing changes in miR-133b
expression. These results also confirm that in mammals, morphine
has the same effect as in the zebrafish in neuronal differentiation
through miR-133b.
FUTURE PERSPECTIVES
There is increasing evidence that miRNAs have a role in the
control and development of many diseases: cancer (He et al.,
2005; Tavazoie et al., 2008, Garzon et al., 2009), cardiovascu-
lar diseases (Zhao et al., 2005), autoimmune diseases (Sonkoly
et al., 2007), neurodegenerative diseases (Fiore et al., 2008), and
numerous others. In clinical practice, miRNAs can be useful as
both diagnostic markers and predictors of therapeutic response
(Garzon et al., 2009). Further research is warranted to elucidate
the interaction between different miRNAs in order to analyze the
possible therapeutic value that these post-transcriptional regu-
lators have. The number of targets predicted for each miRNA
is enormous; for example, using miR and a software, 1704 tar-
gets for miR-133b have been found. Even in this case, where
we have proven that miR-133b is involved in the regulation of
dopaminergic neurons, we need to find out if other physiologi-
cal systems are also involved. If we can confirm different miRNAs
to specifically regulate different targets, and if these miRNAs can
cross-talk producing a functional result, then it is possible that
therapeutic agents can be designed to rationally and specifically
target the entire discovered complexity of the system. Currently,
while inducing or repressing a single miRNA represents a promis-
ing therapeutic strategy for specific diseases, we can not say that
every miRNA known, by itself, could be a potential therapeutic
agent.
The therapeutic value of miRNAs is dictated in part by the
fact that miRNAs that are upregulated in different diseases can be
targeted using anti-miRNAs (antisense oligonucleotides with spe-
cific modifications; Rossbach, 2010). These microRNA inhibitors
(antagomiRs) demonstrate that therapeutic targeting of miRs is
possible, although these inhibitors have not yet been explored
in the specific context of curing drug addiction. Besides this
inhibitory therapeutic approach, indirect methods, such as down-
regulation of specific miRNA biogenesis pathways, could also serve
as therapeutics. In the opposite scenario, when miRNAs downreg-
ulation is responsible for an abnormal function, as is the case
with miRNAs downregulated in tumors, a possible therapeutic
approach could be to restore mature miRNA levels in the abnormal
tissue.
Accordingly, considering our results relating morphine, the mu
opiod receptor, and the dopaminergic system to the miRNA miR-
133b, it might be possible to design a system that could control
the addiction process in which these four entities are involved,
perhaps by rescuing miR-133b levels with the intention of damp-
ening the expression of the downstream targets that positively
impact dopaminergic differentiation and opioid addiction. Fur-
ther research is needed to elucidate the role, and the therapeutic
relevance, of miRNAs in the complexity of the addiction pathway.
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